Breast Cancer Research and Treatment

, Volume 140, Issue 1, pp 135–142 | Cite as

Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer

  • D. Gareth R. Evans
  • Sarah L. Ingham
  • Andrew Baildam
  • Gary L. Ross
  • Fiona Lalloo
  • Iain Buchan
  • Anthony Howell


BRCA1/2 mutation carriers with breast cancer are at high risk of contralateral disease. Such women often elect to have contralateral risk-reducing mastectomy (CRRM) to reduce the likelihood of recurrence. This study considers whether CRRM improves overall survival. 105 female BRCA1/2 mutation carriers with unilateral breast cancer who underwent CRRM were compared to controls (593 mutation carriers and 105 specifically matched) not undergoing CRRM and diagnosed between 1985 and 2010. Survival was assessed by proportional hazards models, and extended to a matched analysis using stratification by risk-reducing bilateral salpingo-oophorectomy (RRBSO), gene, grade and stage. Median time to CRRM was 1.1 years after the primary diagnosis (range 0.0–13.3). Median follow-up was 9.7 years in the CRRM group and 8.6 in the non-CRRM group. The 10-year overall survival was 89 % in women electing for CRRM (n = 105) compared to 71 % in the non-CRRM group (n = 593); p < 0.001. The survival advantage remained after matching for oophorectomy, gene, grade and stage: HR 0.37 (0.17–0.80, p = 0.008)—CRRM appeared to act independently of RRBSO. CRRM appears to confer a survival advantage. If this finding is confirmed in a larger series it should form part of the counselling procedure at diagnosis of the primary tumour. The indication for CRRM in women who have had RRBSO also requires further research.


Breast cancer Mastectomy BRCA Survival 


  1. 1.
    Graeser MK, Engel C, Rhiem K et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27(35):5887–5892PubMedCrossRefGoogle Scholar
  2. 2.
    Metcalfe K, Gershman S, Lynch HT et al (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384–1392PubMedCrossRefGoogle Scholar
  3. 3.
    Malone KE, Begg CB, Haile RW et al (2010) Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 28(14):2404–2410PubMedCrossRefGoogle Scholar
  4. 4.
    Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6(1):R8–R17PubMedCrossRefGoogle Scholar
  5. 5.
    Peto J, Mack TM (2000) High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 26(4):411–414PubMedCrossRefGoogle Scholar
  6. 6.
    Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110(1):189–197PubMedCrossRefGoogle Scholar
  7. 7.
    Abdalla I, Thisted RA, Heimann R (2000) The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer J 6(4):266–272PubMedGoogle Scholar
  8. 8.
    Rubino C, Arriagada R, Delaloge S, Le MG (2010) Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer 102(1):213–219PubMedCrossRefGoogle Scholar
  9. 9.
    Vichapat V, Garmo H, Holmqvist M et al (2012) Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large swedish-population-based study. J Clin Oncol 30(28):3478–3485PubMedCrossRefGoogle Scholar
  10. 10.
    Alkner S, Bendahl PO, Ferno M, Manjer J, Ryden L (2011) Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer 11:114PubMedCrossRefGoogle Scholar
  11. 11.
    Shi YX, Xia Q, Peng RJ et al (2012) Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer. J Cancer Res Clin Oncol 138(4):705–714PubMedCrossRefGoogle Scholar
  12. 12.
    Tilanus-Linthorst MM, Bartels KC, Alves C et al (2006) Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients. Breast Cancer Res Treat 95(2):117–123PubMedCrossRefGoogle Scholar
  13. 13.
    Wang T, Liu H, Chen KX, Xun P, Li HX, Tang SC (2011) The risk factors and prognosis of bilateral primary breast cancer: a comparative study with unilateral breast cancer. Oncol Res 19(3–4):171–178PubMedCrossRefGoogle Scholar
  14. 14.
    Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101(15):1058–1065PubMedCrossRefGoogle Scholar
  15. 15.
    Yi M, Meric-Bernstam F, Middleton LP et al (2009) Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 115(5):962–971PubMedCrossRefGoogle Scholar
  16. 16.
    Ciatto S, Houssami N, Martinelli F, Bonardi R, Cafferty FH, Duffy SW (2008) Second breast cancers in a Tuscan case series: characteristics, prognosis, and predictors of survival. Br J Cancer 99(3):539–544PubMedCrossRefGoogle Scholar
  17. 17.
    Gronwald J, Tung N, Foulkes WD et al (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118(9):2281–2284PubMedCrossRefGoogle Scholar
  18. 18.
    McDonnell SK, Schaid DJ, Myers JL et al (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19(19):3938–3943PubMedGoogle Scholar
  19. 19.
    van Sprundel TC, Schmidt MK, Rookus MA et al (2005) Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93(3):287–292PubMedCrossRefGoogle Scholar
  20. 20.
    Kaas R, Verhoef S, Wesseling J et al (2010) Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg 251(3):488–492PubMedCrossRefGoogle Scholar
  21. 21.
    Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the national cancer data base, 1998–2007. Ann Surg Oncol 17(10):2554–2562PubMedCrossRefGoogle Scholar
  22. 22.
    Tuttle TM, Abbott A, Arrington A, Rueth N (2010) The increasing use of prophylactic mastectomy in the prevention of breast cancer. Curr Oncol Rep 12(1):16–21PubMedCrossRefGoogle Scholar
  23. 23.
    Graves KD, Peshkin BN, Halbert CH, DeMarco TA, Isaacs C, Schwartz MD (2007) Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat 104(3):321–329PubMedCrossRefGoogle Scholar
  24. 24.
    Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180(6):439–445PubMedCrossRefGoogle Scholar
  25. 25.
    Bedrosian I, Hu CY, Chang GJ (2010) Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 102(6):401–409PubMedCrossRefGoogle Scholar
  26. 26.
    Brewster AM, Bedrosian I, Parker PA et al (2012) Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118(22):5637–5643PubMedCrossRefGoogle Scholar
  27. 27.
    Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A (2012) Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol 19(8):2600–2606PubMedCrossRefGoogle Scholar
  28. 28.
    Maurice A, Evans DG, Affen J, Greenhalgh R, Duffy SW, Howell A (2012) Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit. Int J Cancer 131(2):417–425PubMedCrossRefGoogle Scholar
  29. 29.
    Cummings P, McKnight B (2004) Analysis of matched cohort data. The Stata Journal 4(3):274–281Google Scholar
  30. 30.
    Boughey JC, Hoskin TL, Degnim AC et al (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17(10):2702–2709PubMedCrossRefGoogle Scholar
  31. 31.
    Narod SA (2011) The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat 128(2):581–583PubMedCrossRefGoogle Scholar
  32. 32.
    Evans DGR, Lalloo F, Hopwood P, Maurice A, Baildam A, Brain A, Barr L, Howell A (2005) Surgical decisions made by 160 women detected with breast cancer <50 years of age. Eur J Surg Oncol 31(10):1112–1118 Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • D. Gareth R. Evans
    • 1
    • 2
    • 3
  • Sarah L. Ingham
    • 1
    • 6
  • Andrew Baildam
    • 3
    • 4
  • Gary L. Ross
    • 5
  • Fiona Lalloo
    • 1
  • Iain Buchan
    • 6
  • Anthony Howell
    • 1
    • 3
  1. 1.Genesis Breast Cancer Prevention CentreUniversity Hospital of South Manchester NHS TrustManchesterUK
  2. 2.Genetic Medicine, Manchester Academic Health Science Centre (MAHSC)Central Manchester Foundation Trust, St. Mary’s Hospital, The University of ManchesterManchesterUK
  3. 3.Manchester Breast Centre, Manchester Cancer Research CentreThe University of ManchesterManchesterUK
  4. 4.Department of Breast SurgeryUniversity Hospital of South Manchester NHS TrustManchesterUK
  5. 5.Department of Plastic SurgeryThe Christie NHS Foundation TrustManchesterUK
  6. 6.Centre for Health Informatics, Institute of Population HealthThe University of ManchesterManchesterUK

Personalised recommendations